Engelhardt M, MacKenzie K, Drullinsky P, Silver RT, Moore MAS. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 2000; 60:610-617.
MacKenzie KL, Franco S, May C, Sadelain M, Moore MAS. Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp Cell Res 2000, 259:336-350.
Franco S, MacKenzie KL, Dias S, Alvarez S, Rafii S, Moore MAS. Clonal variation in phenotype and lifespan of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT). Exp Cell Research, 2001, 268: 14-25.
Boklan J, Nanjangud G, MacKenzie KL, May C, Sadelain M, and Moore MAS. Limited Proliferation and Telomere Dysfunction Following Telomerase Inhibition in Immortal Murine Fibroblasts. Cancer Research 2002; 62:2104-2114.
MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S, Moore MAS. Multiple stages of malignant transformation of human endothelial cells modeled by co-expression of telomerase reverse transcriptase, SV40 large T antigen and oncogenic N-ras. Oncogene 2002;21:4200-4211.
Franco S, Ozkaynak MF, Sandoval C, Tugal O, Jayabose S, Engelhardt M, Moore MAS. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia 2003. 17:401-410.
Wu K, Orme L, Shaughnessy J, Jacobson JJ, Barlogie B, Moore MAS. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survival. Blood. 2003 101:4982-4989.
Wang ES, Wu K, Chin AC, Pongracz K, Gryaznov S, Moore MAS. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004;103: 258-66.
Gammaitoni L, Weisel KC, Gunetti M, Wu KD, Bruno S, Pinelli S, Bonati A, Aglietta M, Moore MAS, Piacibello W. Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood 2004, 103:4440-8.
